Gilead Sciences to acquire HDV drug developer MYR in €1.4bn deal
Gilead Sciences acquisition of MYR : US biopharma giant Gilead Sciences has agreed to acquire MYR, a German biotech company engaged in developing therapies for chronic hepatitis delta virus (HDV), in a deal worth up to €1.45 billion. The consideration consists of nearly €1.15 billion in cash, which will be paid at the time of […]
Sedana Medical has submitted an application seeking approval for its drug candidate Sedaconda (isoflurane), previously called IsoConDa, for inhaled sedation in intensive care. The application has been filed with the German Medicines Agency BfArM and various other European Medicines Agencies via the DCP procedure. The market approval application is based on the results of the […]
Continue reading …Permira to acquire Spanish pharma company Neuraxpharm from Apax Partners
September 23, 2020 No Comment
Permira, a UK-based private equity firm, said that a company backed by its funds has agreed to acquire Neuraxpharm, a specialty pharma company focused on the treatment of the central nervous system (CNS) from funds advised by Apax Partners. Financial details of the deal were not revealed. Based in Spain and Germany, Neuraxpharm is engaged […]
Continue reading …BioNTech to acquire Novartis’ Marburg manufacturing plant to expand production of COVID-19 vaccine candidates
September 18, 2020 No Comment
Biopharmaceutical New Technologies (BioNTech) has agreed to acquire a GMP certified manufacturing facility in Marburg, Germany from Novartis to expand the production capacity of its BNT162 COVID-19 vaccine candidates. The financial terms of the deal were not revealed by the parties. BioNTech said that the production capacity of its five mRNA COVID-19 vaccine candidates under […]
Continue reading …
Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm for about $562 million. The portfolio to be offloaded to Cheplapharm is made up of non-core prescription pharma products in a range of therapeutic segments. This includes cardiovascular/metabolic and anti-inflammatory […]
Continue reading …
PCI Pharma Services, a drug development solutions provider, is set to expand its global clinical trial services with a new clinical center of excellence (COE) at its Berlin location in Germany. The pharma and biopharma outsourcing solutions provider said that the new center will enable it to grow its clinical supply-chain network into continental Europe […]
Continue reading …
Haemonetics acquisition of enicor : US blood management company Haemonetics has acquired Germany-based medical technology manufacturer enicor, which manufactures the ClotPro whole blood coagulation testing system. Financial terms of the deal were not disclosed. The ClotProblood coagulation testing system is said to be an advanced viscoelastic diagnostic device that delivers more assays than other hemostasis […]
Continue reading …
AdaptHealth, a US home medical equipment provider (HME provider), has agreed to acquire the Patient Care Solutions business from German healthcare and pharma company McKesson. Patient Care Solutions offers wound care supplies, urological supplies, ostomy supplies, incontinence supplies, breast pumps, and diabetic care supplies to patients across 50 states in the US. For the 12 […]
Continue reading …
Takeda Pharmaceutical Company opened a new €130 million vaccine manufacturing plant in Germany at Singen to produce TAK-003, its dengue vaccine candidate. The Singen vaccine manufacturing facility will be used for the formulation, fill, finish and secondary packaging of the TAK-003 dengue vaccine candidate starting with the packaging line. The vaccine plant employs up to […]
Continue reading …Boehringer Ingelheim to initiate phase 2 trial of BI 456906 in obesity, diabetes
September 3, 2019 No Comment
German drugmaker Boehringer Ingelheim will initiate Phase 2 clinical trial of dual-acting GLP-1/glucagon agonist BI 456906 in obesity and diabetes in late 2019. The compound in-licensed from Zealand Pharma is derived from the natural gut hormone oxyntomodulin and activates both the GLP-1 and glucagon receptors to control metabolic activities. The dual agonist BI 456906 with […]
Continue reading …
Business News Today
- Dr. Reddy’s reports success for Russian Covid-19 vaccine Sputnik V
- TCS rolls out Autoscape solution suite for autonomous and connected vehicle experiences
- Infosys Q3 2020 results : Indian IT services giant reports $705m net profit
- Safehold Special Risk acquires motorsports insurance firm WSIB Insurance
- OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo
- Thoma Bravo-backed Majesco acquires insurtech company ClaimVantage
- Tata Power gets LOA from KSEBL for 110MW solar power project in Kerala
- Albemarle to invest up to $50m to double lithium production at Silver Peak facility
- Westland Insurance acquires Nova Scotia-based Storm Insurance Group
- Indian B2B ecommerce platform udaan bags $280m in new funding round
